Bausch + Lomb Corp (BLCO)vsMerck & Company Inc (MRK)
BLCO
Bausch + Lomb Corp
$19.92
-3.30%
HEALTHCARE · Cap: $7.29B
MRK
Merck & Company Inc
$146.72
-0.14%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1166% more annual revenue ($67.38B vs $5.32B). MRK leads profitability with a 3.6% profit margin vs -3.2%. BLCO appears more attractively valued with a PEG of 0.89. BLCO earns a higher WallStSmart Score of 45/100 (D+).
BLCO
Hold45
out of 100
Grade: D+
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.0%
Fair Value
$9.62
Current Price
$19.92
$10.30 premium
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.72
$62.06 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
Weak financial health signals
ROE of -3.4% — below average capital efficiency
Earnings declined 88.6%
Distress zone — elevated risk
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : BLCO
The strongest argument for BLCO centers on Price/Book, PEG Ratio. PEG of 0.89 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BLCO
The primary concerns for BLCO are Piotroski F-Score, Return on Equity, EPS Growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
BLCO profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
BLCO carries more volatility with a beta of 0.56 — expect wider price swings.
BLCO is growing revenue faster at 9.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
BLCO scores higher overall (45/100 vs 44/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bausch + Lomb Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Bausch Lomb Corporation is an eye health company in Canada and internationally. The company is headquartered in Vaughan, Canada.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?